A recent BiotechStockTrader.com article (dtg.fm/SyR6), highlighting the unique and positive position that Boston Therapeutics now holds with regard to the multi-billion dollar diabetes drug industry, laid out the reasons why investors are starting to jump on board the still small biotech company.
The company's lead drug candidate, PAZ320, is the first diabetes drug to be based upon an important new technology, carbohydrate hydrolyzing enzyme inhibiting (CHEI). Unlike traditional diabetes drugs, PAZ320 doesn't require insulin injections, and doesn't involve interaction with important internal organs, such as the pancreas, kidneys, or liver. Instead, it is a simple chewable that operates in the gastrointestinal track, and has already been shown to be dramatically effective at stopping sugar before it even gets into the blood stream.
The article pointed out a number of reasons that Boston Therapeutics could be the next hot drug stock:
•Diabetes drugs are huge money makers, with the top 10 diabetes drugs generating well over $1 billion in annual sales, in some cases over $6 billion.
•The overall diabetes drug market is expected to grow to $58 billion by 2018.
•The number of people with diabetes has exploded over the past 10 years, and is expected to climb to over ½ billion by 2030.
•Type 2 diabetes, that targeted by Boston Therapeutics, represents approximately 95% of all diabetes cases.
•Being the first CHEI diabetes drug, Boston Therapeutics' PAZ320 is clearly differentiated.
•In a Phase II clinical trial of PAZ320 at Dartmouth, 45% of the Type 2 diabetes patients showed a whopping 40% reduction in post-meal glucose.
•PAZ320 is easier to administer, being a simple chewable, and could avoid serious side effects sometimes found in standard drugs that that must interact with vital organs.
•PAZ320 has been shown to be effective regardless of other medications being used by the patient.
For additional information, visit BostonTI.com
MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit disclaimer.missionir.com